Literature DB >> 9234918

Loss of heterozygosity in human ovarian cancer on chromosome 19q.

A Bicher1, K Ault, A Kimmelman, D Gershenson, E Reed, B Liang.   

Abstract

Abnormalities in the function of oncogenes and tumor suppressor genes have been associated with many human malignancies. The recognition of sites of loss of heterozygosity (LOH) has led to the identification of such genes. We previously reported that abnormalities of mRNA expression of ERCC1 and ERCC2 may be characteristic of epithelial ovarian carcinoma and brain tumors. This led to an investigation of chromosome 19q13.2-q13.4 which contains these DNA repair genes. A 7-Mb region was analyzed using six microsatellite repeats. Loss of heterozygosity has been identified in 53% (8/15) of cases at marker D19S246 which lies in a 2-Mb segment between HRC and KLK1. The genetic material both centromeric and telomeric to the region of loss was conserved. This area is telomeric to three DNA repair genes where LIG1 is 1-Mb centromeric and ERCC1 and ERCC2 are 3.5- and 4.0-Mb centromeric, respectively. These findings represent the first report of a biologically significant rate of LOH on chromosome 19q13.2-q13.4 in human ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234918     DOI: 10.1006/gyno.1997.4709

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498.

Authors:  Ravi Kasiappan; Zheng Shen; Anfernee K-W Tse; Umesh Jinwal; Jinfu Tang; Panida Lungchukiet; Yuefeng Sun; Patricia Kruk; Santo V Nicosia; Xiaohong Zhang; Wenlong Bai
Journal:  J Biol Chem       Date:  2012-10-10       Impact factor: 5.157

2.  Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein.

Authors:  K Liu; L Li; P E Nisson; C Gruber; J Jessee; S N Cohen
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  Gene expression profiles of the aurora family kinases.

Authors:  Yong-Shiang Lin; Li-Jen Su; Chang-Tze Ricky Yu; Fen-Hwa Wong; Hsu-Hua Yeh; Su-Liang Chen; Jiunn-Chyi Wu; Wey-Jin Lin; Yow-Ling Shiue; Hsiao-Sheng Liu; Shih-Lan Hsu; Jin-Mei Lai; Chi-Ying F Huang
Journal:  Gene Expr       Date:  2006

4.  Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.

Authors:  Danian Dai; Qiang Li; Pengfei Zhou; Jianjiang Huang; Hongkai Zhuang; Hongmei Wu; Bo Chen
Journal:  Front Cell Dev Biol       Date:  2022-06-13

5.  Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs.

Authors:  James R Brown; Kristin K Koretke; Marian L Birkeland; Philippe Sanseau; Denis R Patrick
Journal:  BMC Evol Biol       Date:  2004-10-12       Impact factor: 3.260

6.  In vivo Engineering of Chromosome 19 q-arm by Employing the CRISPR/AsCpf1 and ddAsCpf1 Systems in Human Malignant Gliomas (Hypothesis).

Authors:  Atefe Abak; Hamed Shoorei; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2021-05-15       Impact factor: 3.444

7.  Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers.

Authors:  T Takahashi; M Futamura; N Yoshimi; J Sano; M Katada; Y Takagi; M Kimura; T Yoshioka; Y Okano; S Saji
Journal:  Jpn J Cancer Res       Date:  2000-10

8.  Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.

Authors:  Ingiridur Skirnisdottir; Markus Mayrhofer; Maria Rydåker; Helena Akerud; Anders Isaksson
Journal:  BMC Cancer       Date:  2012-09-12       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.